Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001–2014: A population-based study

Details

• Alternative Title:
  Pediatr Blood Cancer
• Personal Author:
  Abrahão, R. ; Ribeiro, R.C. ; Lichtensztajn, D.Y. ; Rosenberg, A.S. ; Keegan, T.H.M.
• Description:
  Background: ; This population-based study considered the influence of rituximab on the survival of children (0–19 years), adolescents, and young adults (AYAs, 20–39 years) with diffuse large B-cell lymphoma (DLBCL), including patients with human immunodeficiency virus (HIV) infection. ; Methods: ; Data on 642 children and AYAs diagnosed with DLBCL during 2001–2014 were obtained from the Greater Bay Area Cancer Registry in California. Facility-level reports provided treatment details. The Kaplan–Meier method estimated survival and Cox regression models examined the association between survival and rituximab use, adjusting for sociodemographic and clinical factors. ; Results: ; Rituximab use increased from 2001–2007 to 2008–2014 among children (from 32% to 48%), AYAs (from 68% to 84%), and HIV patients (from 57% to 67%). Five-year survival was higher among children (91%) than AYAs (82%). On multivariable analysis, the hazard of death was 44% lower among rituximab recipients, and higher among uninsured patients, those with HIV, and those with advanced stage at diagnosis. HIV patients who received rituximab were 60% less likely to die than nonrecipients. ; Conclusions: ; Our study suggests a benefit of rituximab on the treatment of AYAs and HIV patients with DLBCL. The worse survival observed among HIV-positive and uninsured patients is of concern and calls for further investigation. Careful consideration should be given on whether to recommend rituximab more often on the front-line treatment of children and HIV-positive patients with DLBCL.
• Subjects:
  • Article
  • AYA
  • children
  • DLBCL
  • population-based study
  • rituximab
  • survival
  • Adolescent
  • Adult
  • Age Factors
  More +
• Source:
  Pediatr Blood Cancer. 66(4):e27559
• Pubmed ID:
  30511461
• Pubmed Central ID:
  PMC9423938
• Document Type:
  Journal Article
• Funding:
  HHSN261201000140C/CA/NCI NIH HHSUnited States/ ; HHSN261201000035C/NH/NIH HHSUnited States/ ; U58 DP003862/DP/NCCDPHP CDC HHSUnited States/ ; 5NU58DP003862-04/DP003862/CC/CDC HHSUnited States/ ; HHSN261201000034C/NH/NIH HHSUnited States/
• Volume:
  66
• Issue:
  4
• Download URL:
  https://stacks.cdc.gov/view/cdc/121158/cdc_121158_DS1.pdf
• File Type:
  [PDF - 283.76 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:c2280757525ce904c8b8678cdd513013db0f5623027378b74cb641e0dae6085c